Considering that the predominant changes in hepatocytes during MASLD involve aberrant lipid metabolism, the expression of a set of critical genes involved in lipid metabolism, lipid biosynthesis [SREBP1 (sterol regulatory element-binding protein 1) and FASN (fatty acid synthase)] and uptake [CD36 (cluster of differentiation 36)], oxidation [PGC1A (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) and CPT1A (carnitine palmitoyltransferase 1a)], and glucose uptake [GLUT2 (glucose transporter type 2)] was analyzed. The gene discussed is CPT1A; the disease is metabolic dysfunction-associated steatotic liver disease.